A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Phase: PHASE4
Conditions: Acute Bacterial Skin and Skin Structure Infections
Sponsor: Allergan

NCT02961764 
 
Study ID: CMO‐US‐ID‐0476 
 
 
Title: A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients with 
Acute Bacterial Skin and Skin Structure Infections – ADVANCE 
 
Protocol Date: 11 Jan 2018 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 1 
Version 3.0  
 
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of 
Patients with Acute Bacterial Skin and Skin Structure Infections 
 
Contacts: 
 
 
Study sponsor: 
Allergan 
2525 Dupont Drive 
Irvine, CA 92612-1599 
Document type 
Study Protocol 
Development phase: 
Phase 4 
Protocol Number:  
CMO-US-ID-0476 
Version:  
3.0 
Release date:  
January 11th 2018 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 3 
Version 3.0  
Signature of Principal Investigator  
 
______________________________________________________________________________ 
 
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients 
with Acute Bacterial Skin and Skin Structure Infections 
______________________________________________________________________________ 
 
Version 3.0 
 
I agree to the terms and conditions relating to this study protocol.  I agree to conduct the 
study according to the protocol and the applicable ICH guidelines and GCP regulations, and to 
inform all who assist me in the conduct of this study of their responsibilities and obligations. 
 
 
Signature: 
______________________________ 
________________ 
 
 
 
 
 
 
 
 
Date 
 
 
 
 
 
 
 
 
DD-MMM-YYYY  
 
 
Name and Title (Print):  ____________________________________________ 
 
This document contains confidential information, which should not be copied, referred to, released 
or published without written approval from Allergan.  Investigators are cautioned that the release of 
the information in this protocol may be subject to change and revision.  
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 4 
Version 3.0  
Table of contents 
List of abbreviations ............................................................................................................ 7 
Protocol synopsis ................................................................................................................. 9 
1 
Introduction ....................................................................................................................... 16 
1.1 
Background ............................................................................................................ 16 
1.1.1 
Skin and skin-structure infections ......................................................... 16 
1.1.2 
Acute bacterial skin and skin structure infections ................................. 16 
1.1.3 
Treatment of ABSSSI ........................................................................... 17 
1.1.4 
Dalbavancin........................................................................................... 17 
1.1.5 
New Critical Pathway ........................................................................... 18 
1.2 
Purpose .................................................................................................................. 18 
2 
Study objectives ................................................................................................................. 18 
2.1 
Primary objective ................................................................................................... 18 
2.2 
Secondary objectives ............................................................................................. 19 
3 
Study design ...................................................................................................................... 20 
3.1 
Overview ............................................................................................................... 20 
3.1.1 
Study duration ....................................................................................... 21 
3.1.2 
Rationale of study design ...................................................................... 21 
3.2 
Antibiotic treatment ............................................................................................... 22 
3.2.1 
Pre-period .............................................................................................. 22 
3.2.2 
Post-period ............................................................................................ 23 
3.2.3 
Rationale of dose/regimen of antibiotic treatment ................................ 23 
3.2.4 
Rationale for choice of comparator ....................................................... 24 
3.3 
Subject identification ............................................................................................. 24 
3.3.1 
Pre-period .............................................................................................. 24 
3.3.2 
Post-period ............................................................................................ 24 
3.3.3 
Subject follow-up .................................................................................. 24 
3.3.4 
Rationale for subject follow-up ............................................................. 25 
3.4 
Subject inclusion and exclusion criteria ................................................................ 25 
3.4.1 
Inclusion criteria .................................................................................... 25 
3.4.2 
Exclusion criteria .................................................................................. 25 
3.5 
Early study termination.......................................................................................... 27 
4 
Measures and data collection ............................................................................................. 28 
4.1 
Study outcomes ...................................................................................................... 28 
4.1.1 
Baseline characteristics ......................................................................... 28 
4.1.2 
Primary and secondary outcomes .......................................................... 31 

Allergan Protocol: CMO-US-ID-0476 
 
Page 5 
Version 3.0  
 
 
4.2 
Data collection ....................................................................................................... 34 
4.2.1 
Data collection schedule ....................................................................... 35 
4.2.2 
Patient Diary Aid................................................................................... 36 
5 
Safety assessments ............................................................................................................. 36 
5.1 
Adverse events ....................................................................................................... 36 
5.2 
Causality assessment ............................................................................................. 37 
5.3 
Severity assessment ............................................................................................... 37 
5.4 
Serious adverse events ........................................................................................... 38 
5.5 
Medication error .................................................................................................... 38 
5.6 
Procedure for collection of adverse events and serious adverse events ................ 39 
5.7 
Procedure for serious adverse event reporting ....................................................... 39 
5.8 
Procedure for medication error reporting .............................................................. 39 
5.9 
Procedures for reporting pregnancies/lactation exposure ...................................... 39 
5.10 
Potential Hy’s Law cases ....................................................................................... 40 
6 
Data analysis ...................................................................................................................... 40 
6.1 
Cost ........................................................................................................................ 40 
6.2 
Handling of missing data ....................................................................................... 41 
6.3 
Sample size and sample size considerations .......................................................... 41 
6.4 
Data monitoring and quality control ...................................................................... 41 
7 
Study sites and study administrative structure .................................................................. 42 
7.1 
Core study team ..................................................................................................... 42 
7.2 
Site study team ....................................................................................................... 42 
8 
Ethical considerations ........................................................................................................ 43 
8.1 
Regulatory and ethical compliance and protection of human subjects.................. 43 
8.2 
Subject confidentiality ........................................................................................... 43 
8.3 
Informed consent procedures ................................................................................. 43 
8.4 
Responsibilities of the investigator and IRB ......................................................... 44 
8.5 
Publication ............................................................................................................. 44 
9 
Protocol deviations and violations ..................................................................................... 44 
9.1 
Protocol amendments............................................................................................. 44 
10  References ......................................................................................................................... 45 
11
 
 
 
 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 6 
Version 3.0  
List of tables and figures 
 
 
Table 2. Baseline characteristics ....................................................................................... 28 
Table 3. Primary and secondary outcomes ........................................................................ 31 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 7 
Version 3.0  
List of abbreviations 
µL 
Microliter 
µmol 
Micromole 
ABSSSI 
Acute bacterial skin and skin-structure infection 
AE 
Adverse event 
AIDS 
Acquired immune deficiency syndrome 
ANC 
Absolute neutrophil count 
BPM 
Beats per minute 
cm2 
Square centimeters 
CrCl 
Creatinine clearance 
CRF 
Case report form 
CRO 
Contract Research Organization 
dL 
Deciliter 
ED 
Emergency department 
ESRD 
End-stage renal disease 
FDA 
Food and Drug Administration 
g 
Gram 
GCP 
Good Clinical Practice 
HCUP 
Healthcare Cost and Utilization Project 
HIV 
Human immunodeficiency virus 
hr 
Hour 
HRQoL 
Health-related quality of life 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
ICU 
Intensive care unit 
IRB 
Institutional review board 
IV 
Intravenous 
kg 
Kilogram 
L 
Liter 
mg 
Milligram 
min 
Minute 

Allergan Protocol: CMO-US-ID-0476 
 
Page 8 
Version 3.0  
mL 
Milliliter 
MRSA 
Methicillin-resistant Staphylococcus aureus 
NIS 
National Inpatient Sample 
OPAT 
Outpatient parenteral antibiotic therapy 
PICC 
Peripherally-inserted central catheter 
q12–24h 
Every 12 to 24 hours 
q12h 
Every 12 hours 
q24h 
Every 24 hours 
q48h 
Every 48 hours 
q6–12h 
Every 6 to 12 hours 
q8–12h 
Every 8 to 12 hours 
q8h 
Every 8 hours 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SF-12 
Short Form-12 Health Survey 
SIRS 
Systemic inflammatory response syndrome 
SOP 
Standard operating procedure 
SSSI 
Skin and skin-structure infection 
TMP 
Trimethoprim 
ULN 
Upper limit of normal 
US 
United States 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 9 
Version 3.0  
Protocol synopsis 
Title of study 
 
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for 
Treatment of Patients with Acute Bacterial Skin and Skin Structure 
Infections 
Rationale 
Treatment of ABSSSI lacks a clear approach to risk stratification of 
patients and management upon patient presentation to the emergency 
department. Lack of a clear approach may cause unnecessary hospital 
admissions of ABSSSI patients, who otherwise could be treated in an 
outpatient setting. A paucity of research exists regarding critical 
pathways in the ED for treatment of ABSSSI patients and the place of 
long-acting parenteral antibiotics. Critical pathways, also known as 
critical paths, clinical pathways, or care paths, are management plans 
that outline steps, such as the sequence and timing of actions, necessary 
for a complex process. Therefore, implementation of a new critical 
pathway may potentially demonstrate benefit compared to usual care 
for the treatment of ABSSSI for patients who could otherwise be 
treated in an outpatient healthcare setting. Long-acting parenteral 
antibiotics may be an important component of the pathway, as a means 
to increase efficiency of ABSSSI treatment. The new critical pathway 
under study is defined as (1) use of guideline-based patient 
identification criteria, and, for those who meet these criteria, (2) use of 
dalbavancin, 
a 
long-acting 
antibiotic 
with 
an 
abbreviated 
administration schedule. 
Objectives 
  
To assess the effect of a new critical pathway compared to usual care 
for the treatment of ABSSSI during initial care (the date of enrollment 
to 14 days) and follow-up (30 days after initial care) on the following 
outcomes: 
Primary outcome 
 Hospital admission rate at initial episode of care 
Secondary outcomes   
 Total admitted hospital days during initial care and follow-up  
 Infection-related total admitted hospital days during initial care 
and follow-up  
 ED length of stay at initial episode of care  
 Infection-related major surgical interventions that required 
operating room time during initial care and follow-up 
 Infection-related hospitalizations during initial care and 
follow-up  

Allergan Protocol: CMO-US-ID-0476 
 
Page 10 
Version 3.0  
 Infection-related hospitalizations during initial care and 
follow-up that resulted in admission to Intensive Care Unit 
(ICU) 
 All cause hospitalizations in the 30 days post discharge from 
the hospital or release from the ED 
 Infection-related ED visits during initial care and follow-up 
 Infection-related outpatient healthcare visits during initial care 
and follow-up 
 Use of a PICC line or central line to administer antibiotic 
therapy during initial care and follow-up 
 Infection-related healthcare visits due to PICC line or central 
line used to administer antibiotic therapy during initial care and 
follow-up 
 Serious adverse events (SAEs) during initial care and follow-
up  
 Patient satisfaction with care 
 Patient work and productivity loss  
 Patient Health-related Quality of Life (HRQoL)  
Population 
Study subjects will be recruited among patients who present to EDs of 
participating sites with ABSSSI and who require coverage for a known 
or suspected Gram-positive infection. Among all such individuals, 
attention will be focused on those who meet all of the inclusion criteria 
and none of the exclusion criteria.  

Allergan Protocol: CMO-US-ID-0476 
 
Page 11 
Version 3.0  
Inclusion criteria 
 Aged ≥18 years 
 Present to the ED and meet clinical definition for ABSSSI 
o Present 
with 
the 
following 
infection 
types: 
cellulitis/erysipelas, 
wound 
infection, 
or 
major 
cutaneous abscess 
o Lesion size area ≥75 cm2 
 Known or suspected infection caused by susceptible isolates of 
the following Gram-positive microorganisms: Staphylococcus 
aureus (including methicillin-susceptible and methicillin-
resistant strains), Streptococcus pyogenes, Streptococcus 
agalactiae, 
Streptococcus 
dysgalactiae, 
Streptococcus 
anginosus group (including S. anginosus, S. intermedius, S. 
constellatus) 
and 
Enterococcus 
faecalis 
(vancomycin 
susceptible strains).  
 Willing and able to return to the hospital or a designated clinic 
for scheduled visits, or to be in contact with study coordinators 
through telephone communication as required by the protocol 
and the antibiotic treatment administered 

Allergan Protocol: CMO-US-ID-0476 
 
Page 12 
Version 3.0  
Exclusion criteria 
 
 
 
 
 
 Known 
or 
suspected 
Gram-negative 
infections 
including 
bacteremia, 
anaerobic 
infections, 
or 
fungemia, even in the presence of Gram-positive 
infection 
 Known or suspected infections that are severe, life-
threatening, or are not included in the ABSSSI FDA 
guidance1, including the following examples:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 13 
Version 3.0  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 Severe neurological disorder leading to severe 
immobility or confined to wheelchair or bed (e.g. 
paraplegia and hemiplegia) 
 Bilateral lower extremity involvement of the 
suspected infection (to exclude patients with chronic 
venous stasis) 
 Unwilling or unable to follow study procedures 
Intervention 
The new critical pathway under study is defined as (1) use of 
guideline-based patient identification criteria, and, for those who 
meet these criteria, (2) use of dalbavancin, a long-acting antibiotic 
with an abbreviated administration schedule. 
Comparator treatment 
Usual care (i.e. investigator choice antimicrobial therapy for a 
suspected or known Gram-positive infection of susceptible 
organisms)  
Study design 
Pre-period versus post-period trial 
Study duration and 
sample size 
The duration of the study will not be predetermined, but rather will 
depend on the number of included sites and eligible subjects at each 
site. Both the pre- and post-periods will run until approximately 322 
subjects are enrolled, or 161 subjects per period. Section 6.3, Sample 
size, provides information on the minimum number of subjects. 
Sites  
This study will be performed at approximately 8 US study centers.  
Baseline characterization 
 Study site characteristics where subject was enrolled 
 Demographics  
 Comorbidities  

Allergan Protocol: CMO-US-ID-0476 
 
Page 14 
Version 3.0  
 Charlson Comorbidity Index  
 Infection type  
o Cellulitis/erysipelas,  
o Wound infection, or  
o Major cutaneous abscess 
 Infection characteristics  
 Healthcare utilization in prior three months 
Outcomes 
 Hospital admission rate at initial episode of care 
 Total admitted hospital days during initial care and follow-up  
 Infection-related total admitted hospital days during initial 
care and follow-up  
 ED length of stay at initial episode of care  
 Infection-related major surgical interventions that required 
operating room time during initial care and follow-up  
 Infection-related hospitalizations during initial care and 
follow-up  
 Infection-related hospitalizations during initial care and 
follow-up that resulted in admission to Intensive Care Unit 
(ICU) 
 All cause hospitalizations in the 30 days post discharge from 
the hospital or release from the ED  
 Infection-related ED visits during initial care and follow-up  
 Infection-related outpatient healthcare visits during initial 
care and follow-up 
 Use of PICC line or central line to administer antibiotic 
therapy during initial care and follow-up 
 Infection-related healthcare visits due to PICC line or central 
line used to administer antibiotic therapy during initial care 
and follow-up 
 Serious adverse events (SAEs) during initial care and follow-
up  
 Patient satisfaction with care  
 Patient work and productivity loss  
 Patient Health-Related Quality of Life (HRQoL)  
 Time spent in observation during initial episode of care  
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 15 
Version 3.0  
 
 
 
 
 
 
 
 
 
 
Data analysis 
Subject characteristics and outcomes will be summarized and 
described for all subjects and compared between the pre- and post-
periods using appropriate statistical methods with adequate power. 
Site characteristics will also be summarized and described. Study 
analyses will be fully described in a separate SAP. 
Data Source and 
Collection 
Case-report forms (CRF) will be developed and employed by trained 
site investigators to prospectively collect information on baseline 
characteristics and outcomes following subject enrollment in the 
study. 
Safety Reporting 
Adverse events (AEs) and serious adverse events (SAEs) will be 
monitored regularly and all SAEs will be reported by each site to the 
sponsor. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 16 
Version 3.0  
1 
Introduction 
1.1 
Background 
1.1.1 
Skin and skin-structure infections 
Skin and skin-structure infections (SSSI) are among the most commonly encountered 
infections in clinical practice, with an estimated 14.2 million outpatient visits for cellulitis 
and abscess reported in 2005 alone.2 The number of visits to the emergency department (ED) 
for SSSI has nearly tripled between 1996 and 2005.3 In recent years,  while some evidence 
suggests that ED visits for ABSSSI in the United States (US) are stabilizing (Pallin 2014),4 
the overall burden of these infections to the US healthcare system remains high—between 
2000-2012, the incidence of patients with at least 1 SSSI-related hospital, ambulatory care, 
and ED visit increased by 38%, 46%, and 56%, respectively.5   
There is evidence that hospital admissions for these infections have also increased 
substantially in recent years.  Based on examinations of the US National Inpatient Sample 
(NIS), Edelsberg and colleagues reported a 29% increase in admissions to hospitals for SSSI 
between 2000 and 2004; increases were greatest among patients aged <65 years (37% vs. 
14% for those aged ≥65 years), urban hospitals (32% vs. 11% for rural hospitals), and among 
those with “superficial” infections (e.g., cellulitis, abscess) (33% vs. 24% for 
deeper/healthcare-associated infections [e.g., post-operative wound infection, infection due 
to vascular device]).6 The Healthcare Cost and Utilization Project (HCUP) 2013 report stated 
that SSSI infections were responsible for over 600,000 hospitalizations annually and were 
considered the eighth-most rapidly growing cause for hospitalization from 1997- 2011.7 
1.1.2 
Acute bacterial skin and skin structure infections 
In an effort to focus on acute infection and increase homogeneity of what had traditionally 
been a relatively diverse population, in 2013 the US Food and Drug Administration (FDA) 
provided guidance to manufacturers developing antibiotics for a subgroup of SSSI known as 
acute bacterial SSSI (ABSSSI). The FDA defined ABSSSI to consist of cellulitis/erysipelas, 
wound infection, and major cutaneous abscess. To be deemed ABSSSI, the infection should 
have a lesion surface area ≥75 squared centimeters (cm2); additional criteria set forth by the 
FDA1 were infection-specific and included: 
 Spreading areas of redness, edema, and/or induration (cellulitis/erysipelas) 
 Purulent drainage from a wound with surrounding redness, edema, and/or induration 
(wound infection) 
 Pus within the dermis or deeper that is accompanied by redness, edema, and/or 
induration (major cutaneous abscess) 
ABSSSI are often caused by Gram-positive pathogens, including but not limited to 
Staphylococcus aureus (both methicillin-resistant [MRSA] and methicillin-susceptible 
strains [MSSA]) and Streptococcus pyogenes.1 

Allergan Protocol: CMO-US-ID-0476 
 
Page 17 
Version 3.0  
1.1.3 
Treatment of ABSSSI 
As with SSSI in general, initial treatment for ABSSSI is typically empiric and based on 
patient characteristics, clinical presentation, treatment guidelines, knowledge of local 
pathogen and resistance patterns, and the antimicrobials that are most likely to be effective 
against them. Given the role of MRSA in this indication, it is not surprising that empiric use 
of anti-MRSA therapy is fairly common; in one recent evaluation of 13,291 patients 
hospitalized for community-acquired complicated SSSI (including but not limited to 
ABSSSI), empiric use of anti-MRSA therapy increased from 61% during 2007 to 73% in 
20108 (p<0.01); Consistent with other research,9 vancomycin was the most commonly used 
agent. 
Patients requiring parenteral antibiotic treatment for ABSSSI have routinely been admitted 
to the hospital, regardless of the degree to which they may require other hospital services 
such as drainage or debridement.9 In one recent examination of 619 adult patients presenting 
to 12 US EDs with SSSI, Talan et al noted that for 85% of patients admitted to the hospital 
(n=94), their doctors indicated that the reason for admission was the requirement for 
parenteral antibiotic therapy, and for approximately 41% of admitted patients (n=39), this 
was the only reason for admission.10 The advent of outpatient parenteral antibiotic therapy 
(OPAT), which has been shown to be a safe and effective means by which parenteral 
antibiotic treatment can be administered,11 has provided an opportunity to rethink this 
paradigm. Current practice guidelines for the management of ABSSSI in EDs and hospitals 
have suggested that patients without a need for admission—defined as presence of 
hemodynamic instability, necrotizing fasciitis, and/or unstable comorbidities—do not require 
admission and instead could be managed as outpatients. Interestingly, these guidelines note 
that the presence of systemic signs of infection such as fever, in the absence of the 
aforementioned risk factors, are not cause in and of themselves for admission.3 Guidelines 
for the selection and management of patients receiving OPAT outline other relevant criteria, 
including psychosocial factors that may threaten the ability to render care on an outpatient 
basis.11 Yet, even with recommendations for outpatient care in clinical guidelines, a lack of 
clear care pathways for ABSSSI patients in the ED limits use in practice.  The development 
of new antibiotic therapies provides the opportunity to successfully design and implement a 
new care pathway, due to the accelerated dosing schedules and ease of administration 
provided by long-acting parenteral antibiotics. Long-acting parenteral antibiotics may be an 
important component of a care pathway in the ED for treatment of ABSSSI. Currently, there 
is a paucity of research that exists regarding a new clinical pathway in the ED for treatment 
of ABSSSI patients and the place of long-acting parenteral antibiotics in therapy.  
1.1.4 
Dalbavancin 
Dalbavancin (Dalvance®) is a novel, long-acting, second-generation lipoglycopeptide that is 
indicated for the treatment of ABSSSI caused by susceptible strains of Gram-positive 
bacteria, including Staphylococcus aureus (both MRSA and MSSA), Streptococcus 
pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus 
group, and Enterococcus faecalis (vancomycin-susceptible strains).12 In two pivotal clinical 
trials, the efficacy and safety of two doses of IV dalbavancin administered one week apart 
(1000 milligrams (mg) for the initial infusion [750 mg for those with renal impairment] 
administered over 30 minutes, 500 mg for the second infusion [375 mg] administered over 

Allergan Protocol: CMO-US-ID-0476 
 
Page 18 
Version 3.0  
30 minutes) were shown to be non-inferior to 10–14 continuous days of therapy with 
vancomycin and linezolid, respectively.12-14 A subsequent clinical trial demonstrated that the 
efficacy and safety of a single dose of dalbavancin administered over a 30 minute infusion 
(1500 mg) was non-inferior to the two-dose regimen.16 Dalbavancin can be provided through 
a peripheral line, and does not necessitate central or PICC placement. 
1.1.5 
New Critical Pathway 
Critical pathways, also known as critical paths, clinical pathways, or care paths, are 
management plans that outline steps, such as the sequence and timing of actions, necessary 
for a complex process. The definition of the new critical pathway for this study was 
developed for the treatment of ABSSSI patients who present to the ED. The new critical 
pathway is (1) use of guideline-based patient identification criteria, and, for those who meet 
these criteria, (2) use of dalbavancin, a long-acting antibiotic with an abbreviated 
administration schedule. Guideline-based patient identification criteria was developed and 
applied based on criteria for identification of ABSSSI and existing OPAT guidelines.3, 11 
Additional patient identification requirements were added to sample selection criteria in order 
to ensure identification of study subjects who likely require parenteral antibiotic therapy.  
1.2 
Purpose  
In addition to a lack of clinical guidelines or critical pathways to inform treatment of ABSSSI 
patients, many contributing factors are responsible for continuing to admit ABSSSI patients 
to receive IV antibiotic therapy, who could otherwise be treated in an outpatient healthcare 
setting. First, physicians may not have experience with or training for use of newer IV 
antibiotics, including use of long-acting IV antibiotics. Information on use of long-acting IV 
antibiotics may be limited to clinical trials, which test agents in highly selected populations 
under optimized settings with limited “real-world” generalizability. Second, physicians may 
have safety concerns related to adequate patient follow-up with the use of long-acting IV 
antibiotics. Third, there may be barriers to provision of OPAT, including institutional time 
spent coordinating care and insurance-related barriers. 
A new study is therefore required to better understand the “real-world” effectiveness of a 
new critical pathway that includes use of a long-acting antibiotic for the treatment of 
ABSSSI. In addition to tangible economic benefits associated with reducing unnecessary 
admissions, implementation of a new critical pathway may increase ED throughput, reduce 
utilization of healthcare services in the outpatient care setting, increase patient satisfaction, 
improve patient health-related quality of life (HRQoL), and reduce patient productivity 
loss/absenteeism. Study objectives 
1.3 
Primary objective 
Estimate the difference in hospital admission rate at initial episode of care comparing 
ABSSSI patients receiving care before implementation of the new critical pathway and after 
implementation.  

Allergan Protocol: CMO-US-ID-0476 
 
Page 19 
Version 3.0  
1.4 
Secondary objectives 
Estimate the difference in the following outcomes during initial care (the date of enrollment 
to 14 days) and follow-up (30 days after initial care) comparing ABSSSI patients receiving 
care before implementation of the new critical pathway and after implementation:  
 Total admitted hospital days during initial care and follow-up  
 Infection-related total admitted hospital days during initial care and follow-up  
 ED length of stay at initial episode of care (time from triage to release from ED) 
 Infection-related major surgical interventions that required operating room time 
during initial care and follow-up (number of expected major surgeries, number of 
unexpected major surgeries, and total number of major surgeries) 
 Infection-related hospitalizations during initial care and follow-up  
 Infection-related hospitalizations during initial care and follow-up that resulted in 
admission to Intensive Care Unit (ICU)  
 All cause hospitalizations in the 30 days post discharge from the hospital or release 
from the ED 
 Infection-related ED visits during initial care and follow-up (number of expected, 
number of unexpected and number of total ED visits during initial care and follow-
up) 
 Infection-related outpatient healthcare visits (e.g., physicians’ office visits, ED visits, 
infusion center visits, home health visits) during initial care and follow-up (number 
of expected visits, number of unexpected and total number of visits) 
 Use of a PICC line or central line to administer antibiotic therapy during initial care 
and follow-up (number of patients who have a PICC or central line placed) 
 Infection-related healthcare visits (e.g., hospitalizations, ED visits, other outpatient 
visits) due to PICC line or central line used to administer antibiotic therapy during 
initial care and follow-up (number of expected visits, unexpected visits and number 
of total visits) 
 Serious adverse events (SAEs) during initial care and follow-up  
 Patient satisfaction with care (subject reported)  
 Patient work and productivity loss (subject reported) 
 Patient Health-related Quality of Life (HRQoL) (subject reported) 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 20 
Version 3.0  
2 
Study design 
2.1 
Overview 
This study will employ a “pre-post” pragmatic design, which will consist of both a pre-
period, or an observational baseline period, and a post-period, or an interventional period 
(Figure 1). During the pre-period, each participating site will implement the first component 
of the critical pathway through implementation of guideline-based criteria to identify patients 
at the point of care in the ED, obtain informed consent, and monitor enrolled subjects. Sites 
will initiate treatment for ABSSSI with “usual care,” defined as site- or physician-specific 
antibiotic treatment of ABSSSI with coverage for a known or suspected Gram-positive 
infection (e.g., vancomycin, linezolid, and daptomycin) to each study subject who meets all 
inclusion and exclusion criteria. Blinding of treating physician to subject enrollment in the 
study during the pre-period will ensure unbiased provision of usual care. During the “post” 
period, for all subjects who provide informed consent and are subsequently enrolled, each 
participating site will additionally implement the second component of the new critical 
pathway, use of dalbavancin, at the point of care in the ED to each study subject who meets 
all inclusion and exclusion criteria.  
As the study is pragmatic in nature, selection criteria will be minimal and designed to 
maximize the selection of “real-world” patients who are ideal candidates for treatment in the 
outpatient healthcare setting, but who are currently admitted to the hospital to receive 
treatment for ABSSSI. Site training is necessary for both adherence to the protocol and 
implementation of the new critical pathway, described in greater detail in Section 7, Study 
sites and administrative structure. Briefly, the core study team in conjunction with members 
of the contract research organization (CRO) will provide training to other members of the 
site study team, including all participating site physicians and other  healthcare providers (i.e. 
nurses, pharmacists, and other staff) on protocol adherence and implementation of the new 
critical pathway. Protocol training will occur before enrolling subjects in both the pre- and 
the post-period. Before enrolling subjects in the post-period, training on implementation of 
the new critical pathway will occur over a two- to four-week period after the date of the last 
enrolled subject in the pre-period. In addition, ongoing reminders and orientations will be 
scheduled for sites as needed during both the pre- and post-period. 
For both periods of interest, subject follow-up will begin on the day of study enrollment and 
end 44 days subsequently. This will reflect the 10 to 14-day period during which antibiotics 
are anticipated to be required for care of ABSSSI plus an additional 30 days to ascertain 
outcomes, such as health resource utilization.  
 
 
 
 
 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 21 
Version 3.0  
2.1.1 
Study duration 
The duration of the study will not be predetermined, but rather will depend on the number of 
included sites and eligible subjects at each site. Both the pre- and post-periods will run until 
the minimum number of subjects are enrolled. Refer to Section 6.3, Sample size, for 
information on the minimum number of subjects. 
2.1.2 
Rationale of study design 
The design of this study allows for a site to understand baseline treatment patterns for 
ABSSSI, then after this period, to implement an institution-level intervention (i.e., each site 
contributes study subjects to both treatment arms), as opposed to concurrently across sites 
(i.e., each site contributes study subjects to a single arm). Use of this design removes site-
level variables as a source of potential confounding and enables comparisons of the new 
critical pathway to usual care in the same setting(s) and similar subject populations.  
The study is designed in a “pragmatic” fashion (i.e., minimal inclusion/exclusion criteria, 
which will enable an examination of the impact of the new critical pathway under “real-
world” conditions, with good generalizability/applicability to clinical practice. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 22 
Version 3.0  
In order to account for temporal trends, sites will also be required to generate data, or reports, 
on admission rates during the pre- and post-period for other infections, including diabetic 
foot infections (currently part of exclusion criteria) and pneumonia (a non-skin infection). 
This will aid in supporting a true difference in outcomes during the pre-period versus the 
post-period based on the new critical pathway for ABSSSI. 
2.2 
Antibiotic treatment  
2.2.1 
Pre-period 
During the pre-period each participating site will be required to initiate treatment for ABSSSI 
with “usual care,” defined as investigator’s choice of antibiotic therapy (e.g., vancomycin, 
linezolid, and daptomycin), to each study subject who meets all study selection criteria. It is 
expected that choice of usual care will be site or physician specific. Dosing of each antibiotic 
agent should follow recommended guidelines, demonstrated for antibiotic agents in, but not 
limited to, Table 1 below. All included subjects require Gram-positive antimicrobial 
coverage for a known or suspected infection caused by susceptible isolates of the following 
microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-
resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus 
dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. 
constellatus) and Enterococcus faecalis (vancomycin susceptible strains).   

Allergan Protocol: CMO-US-ID-0476 
 
Page 23 
Version 3.0  
2.2.2 
Post-period 
During the post-period, all enrolled subjects will receive treatment for ABSSSI with 
dalbavancin at each participating site. Dalbavancin will be administered as a single IV dose 
of 1500 mg over 30 minutes (1125 mg over 30 minutes if CrCl <30 mL/min, for those not 
on regularly scheduled dialysis).12 Dalbavancin will be provided to sites by study sponsor.  
2.2.3 
Rationale of dose/regimen of antibiotic treatment  
Usual care antibiotic therapy and dalbavancin will each be administered per relevant 
guidelines/manufacturer instructions (dosing provided in Table 1). Duration of treatment 

Allergan Protocol: CMO-US-ID-0476 
 
Page 24 
Version 3.0  
with usual care will be left to the physician’s discretion, as recommendations for several 
agents include a range (e.g., 10–14 days for linezolid).24  
2.2.4 
Rationale for choice of comparator 
Usual care will comprise investigator’s choice of care and may therefore vary from subject 
to subject. This was selected to allow for comparisons of the new critical pathway, which 
includes use of dalbavancin, with “real world” treatment. 
2.3 
Subject identification 
Patients presenting to the ED with an ABSSSI infection during both the pre- and post-periods 
will be assessed for inclusion and exclusion criteria. These criteria will be prepared as an 
annotated checklist for the study coordinator and/or study nurses to implement and document 
using a CRF. Information obtained through the annotated checklist coupled with physician 
assessment will define guideline-based patient identification criteria. 
2.3.1 
Pre-period 
During the pre-period, the study coordinator and/or other study nurses will identify patients 
who may be eligible for the study. All hospital staff may be reminded (through posters or 
memorandums) to inform the study coordinator and/or other study nurses as soon as an 
ABSSSI patient is seen in the ED. The study coordinator will implement inclusion and 
exclusion criteria for the new critical pathway by patient interview and/or chart review. 
Inclusion criteria includes measurement of lesion size through a physician assessment 
(Appendix A), and clinical judgment that patient requires coverage for a known or suspected 
Gram-positive infection. Patients who meet all inclusion criteria and none of the exclusion 
criteria based on study coordinator assessment will be enrolled in the study or flagged for 
further review by core study team physicians, who will make the final enrollment decision. 
The treating physician will be blinded to protocol content and study enrollment decision. 
Study coordinator will then complete all additional elements of enrollment, including 
informed consent, and scheduling of follow-up.  
2.3.2 
Post-period 
During the post-period, the study coordinator and/or other study nurses will identify patients 
who may be eligible for the study. As in the pre-period, physicians or other appropriate 
healthcare providers may also identify subjects who are eligible for the study. All hospital 
staff may be reminded (through posters or memorandums) to inform the study coordinator 
and/or other study nurses as soon as an ABSSSI subject is seen in the ED. The study 
coordinator or treating physician will implement the checklist and enroll subjects into the 
study. Study coordinator will then complete enrollment, including informed consent, and 
scheduling of follow-up. 
2.3.3 
Subject follow-up 
Within both the pre- and post-periods, follow-up for each subject will begin on the day of 
enrollment (which is anticipated to be the date of treatment initiation) and conclude 44 days 
thereafter. Follow-up will therefore include the presumed “episode” of antibiotic therapy for 
ABSSSI (up to 14 days) and subsequent 30-day period.  

Allergan Protocol: CMO-US-ID-0476 
 
Page 25 
Version 3.0  
2.3.4 
Rationale for subject follow-up 
Each subject will be followed for a 14-day period (i.e. initial care), which is the longest 
supported duration of antibiotic therapy for ABSSSI treatment.15 In order to allow similar 
opportunity for collection of outcomes in the pre- and the post-period, the post-period 
similarly assumes 14 days. The addition of 30 days after initial care (i.e. follow-up) was 
thought to comprehensively assess outcomes during a relevant timeframe after the 
completion of antibiotic therapy. Therefore, 44 days (initial care and follow-up) for each 
subject encompasses both the maximum treatment duration and assessment of relevant 
outcomes in the 30 days following treatment.  
2.4 
Subject inclusion and exclusion criteria 
Study subjects will be recruited among patients who present to EDs of participating sites with 
ABSSSI and who require coverage for a known or suspected Gram-positive infection. 
Among all such individuals, attention will be focused on those who meet all of the inclusion 
criteria and none of the exclusion criteria.  
2.4.1 
Inclusion criteria 
Eligible study subjects satisfy all of the following inclusion criteria1,10,11,24 
 Aged ≥18 years 
 Present to the ED and meet clinical definition for ABSSSI10-11 
o Present with the following infection types: cellulitis/erysipelas, wound infection, 
or major cutaneous abscess 
o Lesion size area requirements, as measured manually by the length multiplied by 
perpendicular width of wound (Appendix A). 
 Lesion size area ≥75 cm2 
 Known or suspected infection caused by susceptible isolates of the following Gram-
positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and 
methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, 
Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. 
intermedius, S. constellatus) and Enterococcus faecalis (vancomycin susceptible strains).  
 Willing and able to return to the hospital or a designated clinic for scheduled visits, or be 
in contact with the study coordinator through telephone communication, as required by 
the protocol and the antibiotic treatment administered 
2.4.2 
Exclusion criteria 
Study subjects with any of the following criteria will be excluded1,12-14, 26-28,29 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 26 
Version 3.0  
 Known or suspected Gram-negative infections including bacteremia, anaerobic infections, or 
fungemia, even in the presence of Gram-positive infection     
 Known or suspected infections that are severe, life-threatening, or are not included in the 
ABSSSI FDA guidance, including the following examples: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 27 
Version 3.0  
 Injection drug users presenting with a fever 
 
 
 
 
 Severe neurological disorder leading to severe immobility or confined to wheelchair or 
bed (e.g. paraplegia and hemiplegia) 
 Bilateral lower extremity involvement of the suspected infection (to exclude patients 
with chronic venous stasis) 
 Unwilling or unable to follow study procedures 
2.5 
Early study termination 
A premature discontinuation will occur when a subject who signed the informed consent 
form (ICF) ceases participation in the study, regardless of circumstances, before the 
completion of all study assessments (i.e., before completing all protocol-stipulated 
activities). Subjects can be prematurely discontinued from therapy after careful 
consideration for any one of the following reasons: 
 
 Screen failure  
 Failure to receive complete critical pathway by not receiving dalbavancin in the post-
period 
 Withdrawal of consent (a clear reason will be documented) 
 AE (before or after administration of first dose of antibiotic therapy) 
 Protocol deviation/violation, including lack of protocol compliance 
 Lost to follow-up (every effort will be made to contact the subject) 
 Study or site prematurely terminated by the sponsor for any reason 
 If a Gram-negative infection including bacteremia, an anaerobic infection, or fungemia 
develops during the study, or is subsequently found to have been present at baseline, the 
subject should be removed from study treatment and receive appropriate antibiotic(s) to 
treat the Gram-negative infection, anaerobic infection, or fungemia.  
 Other reasons, such as specified administrative reasons or pregnancy 
All subjects who prematurely discontinue from the study, regardless of cause, 
should have a final assessment at early termination (ET). A final assessment will be 
                                                 
a If the patient is a woman of child-bearing potential, from at least the first dose of study drug until the final visit she 
must confirm strict abstinence from sexual intercourse with any male or must confirm use of an effective contraceptive 
method from the following list: A barrier (condoms, diaphragm or cervical cap) with spermicide; Oral or similar 
contraceptive, which includes, but is not limited to: injectable, implanted, or patch hormone therapy, and intrauterine 
device (IUD); Documented surgical sterilization at least 4 weeks prior to baseline; Partner vasectomy at least 6 months 
prior to baseline. 
 
Within these limits, the specific form of contraception employed are left to the discretion of the patient, and/or the 
principal investigator, and/or the patient’s physician. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 28 
Version 3.0  
defined as either a physical visit or a telephone call that completes the evaluations 
scheduled for the Final Visit at the end of study (Day 44 visit; refer to Section 4.2, Data 
collection), or an earlier visit, depending on the visit schedule and when ET occurs. 
Subjects who do not complete all scheduled visits/procedures will be requested to have an 
ET Visit. A clear description will be documented and source documentation will be kept by 
the investigator. The reasons for premature discontinuation from the study will be reflected 
on the Study Termination page of the CRF.  
3 
Measures and data collection 
3.1 
Study outcomes 
3.1.1 
Baseline characteristics 
Baseline characteristics will be collected following subject enrollment into the study, and 
will be based on physical examination and medical history. A complete list of baseline 
characteristics is shown in Table 2. 
Table 2. Baseline characteristics 
Measure Type 
Description 
Demographics 
Age (in years)  
Gender  
Ethnicity/Race  
Employment status 
Location subject presents from (e.g. from 
home, LTC, SNF, nursing home) 
Comorbidities 
Morbid obesity (Body Mass Index)  
Myocardial infarction 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Rheumatologic disease 
Peptic ulcer disease 
Mild liver disease 
Diabetes without complications 
Diabetes with complications 
Renal disease 
Moderate or severe liver disease (Child- 
Pugh Class B and C) 

Allergan Protocol: CMO-US-ID-0476 
 
Page 29 
Version 3.0  
Measure Type 
Description 
Any malignancy, including leukemia and 
lymphoma 
Metastatic solid tumor 
If subject has cancer, whether active vs. 
remitted/cured 
Alcohol/drug abuse/illicit needle use 
Malnutrition  
HIV 
Immunocompromising conditions other 
than HIV, including: 
 Prescribed ≥20 mg prednisone 
per day 
 Prescribed TNF inhibitors (i.e. 
infliximab or adalimumab) 
 Transplant recipient 
 Active chemotherapy 
Altered mental status 
Lymphedema or chronic venous stasis 
Peripheral Vascular Disease 
Charlson Comorbidity Indexb (CCI)  
Derived variable based on recorded 
comorbidities:  Calculation of the CCI for 
each subject at baseline to assess the risk of 
1 year mortality  
Infection type 
Cellulitis/erysipelas, wound infection, or 
major cutaneous abscess 
Infection characteristics 
Lesion size and location 
Thrombocytopenia (<150,000 platelet 
count or site-specific definition) 
Hyperglycemia (>120mg/dL blood glucose 
or site-specific definition) 
Hyponatremia (<135 mEq/L blood sodium 
or site-specific definition) 
Acidosis (<7.35 pH of the blood or site-
specific definition or described in medical 
chart) 
Uremia (as described in medical chart) 
                                                 
b Deyo et al 1992 

Allergan Protocol: CMO-US-ID-0476 
 
Page 30 
Version 3.0  
Measure Type 
Description 
Anemia (14-18 g/dL hemoglobin for men 
or 12-16 g/dL hemoglobin for women or 
site-specific definition) 
Fever (>98.6 degrees Fahrenheit or site-
specific definition) 
SIRS criteriac at triage, including highest or 
lowest recorded RR and highest or lowest 
recorded BPM in ED/highest or lowest 
recorded fever in the ED/highest or lowest 
WBC count in the ED or amount of 
immature cells in the ED 
Highest or lowest recorded BP at triage in 
the ED 
Laboratory results at baseline and during 
follow-up (e.g. Total white blood cell count, 
hemoglobin, 
sodium, 
glucose, 
serum 
creatinine, and C-reactive protein) 
Rapid microbial assay and microbiological 
culture results and type of culture (i.e. blood, 
wound swab, urine) at baseline and during 
follow-up 
Presence of recurrent infection (evidence 
from chart review, provider assessment and 
subject report of a similar ABSSSI in the 
same location on the body) and any ABSSSI 
infections in the prior 6 months 
Healthcare utilization in prior three months
Hospitalizations and primary reason  
Surgical interventions and primary reason 
Admission to the ICU and primary reason 
ED visits or other outpatient visits (e.g., 
infusion center and physician’s office) and 
primary reason 
Use of dialysis 
Use of any medications for chronic diseases 
and specifically use of an antibiotic 
medication 
Prior antibiotic treatment failure  
                                                 
c SIRS criteria include abnormalities in temperature, heart rate, respiration, and white blood cell count. Specifically, 
fever >38.0°C or hypothermia <36.0°C, tachycardia >90 beats/minute, tachypnea >20 breaths/minute or PaCO2 of less 
than 32mmHg, abnormal white blood cell count leukocytosis >12,000/microliter, leucopoenia <4,000/microliter, or 
>10% immature cells (bands).26,27 

Allergan Protocol: CMO-US-ID-0476 
 
Page 31 
Version 3.0  
Measure Type 
Description 
Receipt of wound care for the presenting 
infection 
3.1.2 
Primary and secondary outcomes 
Primary and secondary outcomes are presented in in Table 3. Outcomes will be assessed 
during initial care (the date of enrollment to 14 days) and follow-up (30 days after initial 
care) unless otherwise specified. 
Table 3. Primary and secondary outcomes 
Measure  
Description 
Hospital admission rate at initial episode of 
care 
The rate of initial hospitalization for the 
treatment of ABSSSI 
Total admitted hospital days during initial 
care and follow up  
 
Includes days during the initial 
hospitalization (for those initially 
hospitalized) and all other hospitalizations  
Infection-related total admitted hospital 
days during initial care and follow up  
Includes days during the initial 
hospitalization (for those initially 
hospitalized) and all other infection-related 
hospitalizations  
ED length of stay at initial episode of care 
(time from triage to release from ED) 
 
Time spent in ED in hours from triage to 
release (either admitted to the hospital, 
admitted to observation, or released to 
home) 
Infection-related major surgical 
interventions that required operating room 
time during initial care and follow up 
Number of major unexpected surgeries 
Number of major expected surgeries 
Number of all major surgical interventions 
unexpected or expected 
Infection-related hospitalizations during 
initial care and follow up 
Number of infection-related 
hospitalizations  

Allergan Protocol: CMO-US-ID-0476 
 
Page 32 
Version 3.0  
Measure  
Description 
Infection-related hospitalizations during 
initial care and follow-up that resulted in 
admission to Intensive Care Unit (ICU) 
 
Number of infection-related 
hospitalizations resulting in admission to 
the ICU. 
All cause hospitalizations in the 30 days 
post discharge from the hospital or release 
from the ED 
Number of all hospitalizations for subjects 
discharged from the ED and re-
hospitalizations for subjects who had an 
initial hospital admission  
 
Infection-related ED visits during initial 
care and follow up 
Number of unexpected visits to ED  
Number of expected visits to ED  
All visits (unexpected and expected) to ED  
Infection-related outpatient healthcare 
visits (e.g., physicians’ office visits, ED 
visits, infusion center visits, home health 
visits) during initial care and follow up 
Unexpected visits, by site (e.g., physicians’ 
office visits, ED visits, infusion center 
visits, home health visits) 
Expected visits, by site (e.g., physicians’ 
office visits, ED visits, infusion center 
visits, home health visits) 
All visits (unexpected and expected), by 
site (e.g., physicians’ office visits, ED 
visits, infusion center visits, home health 
visits) 
Use of PICC line or central line to 
administer antibiotic therapy during initial 
care and follow up 
PICC line or central line placement for 
antibiotic therapy 
Infection-related healthcare visits (e.g., 
hospitalizations, ED visits, other outpatient 
visits) due to PICC line or central line used 
Unexpected visits due to PICC line (i.e. 
complications) 
Expected visits due to PICC line (i.e. initial 
placement, monitoring of PICC line) 

Allergan Protocol: CMO-US-ID-0476 
 
Page 33 
Version 3.0  
Measure  
Description 
to administer antibiotic therapy during 
initial care and follow up 
 
All visits due to PICC line (both 
unexpected and expected visits) 
Serious adverse events (SAEs) during 
initial care and follow-up  
All SAEs as defined in Section 5 Safety 
assessments 
Patient satisfaction with care (subject 
reported) 
Patient satisfaction with care (Subject-
reported, Section 11.2- questionnaire 
similar to the final implemented version) 
Patient work and productivity loss (subject 
reported) 
Number of days with lost/reduced 
productivity during follow-up, as measured 
through Work Productivity and Activity 
Impairment Questionnaire (Section 11.4)30 
Patient Health-Related Quality of Life 
(HRQoL) (subject reported) 
Health-related quality of life (subject 
reported), as measured through the Medical 
Outcomes Study Short Form-12 (SF-12), 
with acute recall (1 week recall) (Section 
11.5)31  

Allergan Protocol: CMO-US-ID-0476 
 
Page 34 
Version 3.0  
3.2 
Data collection 
Information on baseline characteristics, outcomes, and other measures will be collected 
following subject enrollment in the study and will be based on the medical record and CRFs 
that will be developed exclusively for use in this study.  
Data collection will involve the use of the CRO’s electronic data capture (EDC) system 
through use of CRFs, to which only authorized personnel will have access. Subject’s data are 
to be entered into the EDC system by the investigator or designee using their assigned EDC 
user account. After data entry into the EDC system by the investigator or designee, a 
combination of manual and programmatic edit checks will be used to review the data for 
completeness, logic, and adherence to study protocol. As a result of these edits checks, data 
monitoring, and reviews, queries may be electronically issued to the site and should be 
answered electronically via the EDC system. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 35 
Version 3.0  
3.2.1 
Data collection schedule 
Table 5 describes expected follow-up. Follow-up visits will be scheduled for 24 hours after 
enrollment (post-period only), between 48-72 hours after enrollment (post-period only), 14 
days after enrollment (both periods), and 44 days after enrollment (both periods). The follow-
up visits during the post-period include a telephone call at 24 hours and a limited physical 
visit at 48-72 hours. However, for subjects unable to be seen back at the site, a telephone 
interview will suffice at 48-72 hours. Research data will be collected through follow-up visits 
at 14 days (telephone call can occur between 14 and 21 days from enrollment) and at 44 days 
(telephone call can occur between 44 and 51 days from enrollment), through a telephone 
interview of the subject in both the pre- and post-periods. Additionally, electronic medical 
chart data will be reviewed at the 14 day and 44 day time points from enrollment. Any 
additional visits to the visit schedule below will be at the discretion of the subject and treating 
physician.  

Allergan Protocol: CMO-US-ID-0476 
 
Page 36 
Version 3.0  
3.2.2 
Patient Diary Aid 
Patients will be provided with a bound, paper diary to record specific information about their 
health status on days in which they have an interaction with a health care provider.  The diary 
is intended only as an aid to help patients remember details about health care appointments, 
medications, and medical tests. The diary will not be collected by or returned to study staff.   
4 
Safety assessments 
At each visit, subjects are to be queried regarding any adverse events (AEs) or serious adverse 
events (SAEs) that have occurred since the previous visit. Subjects will be asked to volunteer 
information with a nonleading question such as, “How do you feel since your last visit?” 
Study site personnel will record all pertinent information in the subject’s CRF. All AEs will 
be recorded on the appropriate AE reporting page of the subject’s CRF whether or not they 
are considered causally related to the study drug (any antibiotic given for ABSSSI from 
enrollment, including the pre-period). 
For every AE, the investigator will: 
 Provide an assessment of the seriousness of the event (i.e., is it an SAE?), as well as 
the severity and causal relationship 
 Document all actions taken with regard to the study drug 
 Detail any other treatment measures taken for the AE 
 Document the outcome of the AE 
In addition, subjects will be reminded, as described in the ICF to notify site personnel of any 
AEs occurring from the time the subject signed the ICF until the final follow-up visit. Any 
AEs that are ongoing at the time of the final protocol-defined study visit will be followed 
until the condition returns to pre-study status, has resolved or stabilized, or can be explained 
as being unrelated to the study drug. If a follow-up visit is deemed necessary for appropriate 
safety surveillance, it will take place within 30 days of the final protocol-defined study visit. 
4.1 
Adverse events 
An AE is any untoward medical occurrence in a patient or clinical trial subject administered 
a pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 37 
Version 3.0  
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of 
a product, whether or not considered related to the product. The definition of an AE includes: 
 Worsening of a pre-existing condition or underlying disease  
 Events associated with the discontinuation of the use of a product(s), (e.g., appearance 
of new symptoms) 
Please note hospital admissions and/or medical/surgical procedures scheduled prior to 
consenting, but occurring during the study will not be captured as AEs, but will be listed in 
the medical history if related to a pre-existing condition. AEs or abnormal test findings will 
be followed until the event (or its sequelae) or the abnormal test finding resolves or stabilizes 
at a level acceptable to the sponsor/investigator. 
4.2 
Causality assessment 
For each AE, the investigator will provide an assessment of causal relationship to the study 
drug. The causality assessment will be recorded on the appropriate AE reporting page of 
the subject’s CRF. Causal relationship will be assessed by answering the following 
question: 
Is there a reasonable possibility the study drug caused the event? 
Yes: 
There is evidence to suggest a causal relationship between the study drug and 
adverse event; i.e.:  
 There is a reasonable temporal relationship between the study drug and the event, 
and/or  
 The event is unlikely to be attributed to underlying/concurrent disease, other study 
drugs, or other factors, and/or 
 Positive dechallenge and/or rechallenge exist 
 
No: 
There is no evidence to suggest a causal relationship between the study drug 
and adverse event, i.e.: 
 There is no reasonable temporal relationship between the study drug and the event, 
or 
 The subject did not take the study drug, or 
 The event is likely to be attributed to underlying/concurrent disease, other study 
drugs, or other factors, or 
 The event is commonly occurring in the (study) population independent of study drug 
exposure 
4.3 
Severity assessment 
The investigator will provide an assessment of the severity of each AE by recording a severity 
rating on the appropriate AE reporting page of the subject’s CRF. Severity, which is a 
description of the intensity of manifestation of the AE, is distinct from seriousness, which 

Allergan Protocol: CMO-US-ID-0476 
 
Page 38 
Version 3.0  
implies a subject outcome or AE-required treatment measure associated with a threat to life or 
functionality. Severity will be assessed according to the following scale: 
Mild: 
Minor awareness of signs or symptoms that are easily tolerated without specific 
medical intervention 
Moderate: Discomfort that interferes with usual activities and may require minimal 
intervention 
Severe: 
Significant signs or symptoms that are incapacitating with an inability to work or 
perform routine activities and/or that require medical intervention 
4.4 
Serious adverse events 
An SAE is any untoward medical occurrence that at any dose:  
 Results in death 
 Is life-threatening (i.e., the subject was, in the opinion of the investigator, at 
immediate risk of death at the time of the event, it does not refer to an event that 
hypothetically might have caused death if more severe)  
 Requires inpatient hospitalization or prolongation of existing hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
 Is an important medical event that might not be immediately life threatening or result 
in death or hospitalization but might jeopardize the subject or might require 
intervention to prevent one of the other outcomes listed above. Examples of such 
events are intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization 
or development of dependency or abuse. 
In general, hospitalization signifies that the participant has been detained (usually involving 
at least an overnight stay) at the hospital for observation and/or treatment that would not 
have been appropriate in the physician’s office or outpatient setting.  
Emergency room visits that do not result in hospitalization should be evaluated for one of the 
other serious outcomes to determine whether they qualify as SAEs. 
4.5 
Medication error 
Medication error refers to any unintended error in the dosing and/or administration of the 
study drug as per instructions in the prescribing information.  Medication errors generally 
fall into 4 categories as follows: 
 Wrong drug 
 Wrong dose (including dosing regimen, strength, form, concentration, amount); 
 Wrong route of administration; 

Allergan Protocol: CMO-US-ID-0476 
 
Page 39 
Version 3.0  
 Wrong subject (i.e. not administered to the intended subject). 
Medication Errors include occurrences of overdose and underdose of the study drug. 
4.6 
Procedure for collection of adverse events and serious adverse events   
All nonserious AEs and SAEs that occur in a subject from the time he or she signs the ICF 
until the final follow-up visit will be assessed and recorded on the source documents and 
CRF, regardless of causal relationship to the study drug. 
4.7 
Procedure for serious adverse event reporting  
All SAEs that occur in a subject from the time he or she signs the ICF until the final follow-
up visit will be reported to the sponsor within 24 hours of awareness of the event using the 
provided SAE Report Form. The completed SAE Report Form will be sent directly to the 
sponsor by emailing
. In addition to completing the SAE 
Report Form, each SAE will be entered on the appropriate page of the CRF. The investigator 
will assess the causality for each SAE. 
When death occurs with an SAE, the cause of death will be reported as an SAE. “Fatal” will 
be reported as the outcome for these events. 
The sponsor will contact the investigator, if necessary, to clarify any of the event information. 
The investigator will provide any follow-up information for the event to the sponsor on an 
updated SAE report form as soon as it becomes available. 
If the investigator is notified of a SAE that occurs post-study period, that he or she wishes to 
report to the sponsor (e.g., an event suspected to be causally related to the study drug), the 
event will be reported through the process described above.  
Where appropriate, if required by local regulations or procedures, the investigator will report 
these events to the Institutional Review Board (IRB)/Ethics Committee (EC) and/or national 
regulatory authority in addition to the sponsor. 
4.8 
Procedure for medication error reporting  
Medication errors with or without an associated AE will be recorded as medication errors in 
the CRF. SAEs associated with medication errors will be reported to the sponsor as 
described in Section 5.7. 
4.9 
Procedures for reporting pregnancies/lactation exposure  
Occurrences of pregnancy/lactation exposure in a subject should be reported within 24 hours. 
In cases where a pregnancy/lactation exposure occurs with a SAE, the SAE report form 
should be used to report the SAE and the Pregnancy Reporting form should be used to report 
the pregnancy.  
When a pregnancy occurs without any concurrent SAE, the Pregnancy Reporting form will 
be submitted alone. The pregnancy will be followed through to outcome of pregnancy, 
including spontaneous or voluntary termination, details of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or newborn 

Allergan Protocol: CMO-US-ID-0476 
 
Page 40 
Version 3.0  
complications. Any pregnancy discovered from the time of consent to follow-up will be 
reported.  
4.10 
Potential Hy’s Law cases  
Every subject that meets potential Hy’s law criteria,  
• 
ALT or AST >/=3xULN AND  
• 
Total Bilirubin >/=2xULN AND  
• 
Alkaline Phosphatase <2xULN 
occurring anytime from the time he or she signs the ICF for the trial until the final follow 
up visit, investigators will notify the sponsor immediately when all the above criteria have 
been met. A potential Hy’s law case will be sent directly to the sponsor by emailing IR-
clinical-SAE@allergan.com on an AE of Special Interest Form along with the SAE Report 
Form as soon as possible (within 24 hours of learning of the potential Hy’s law). The CRF 
for potential Hy’s law cases will be completed within seven calendar days. Every effort to 
determine the cause of the liver enzyme abnormalities will be made, and close monitoring 
will be initiated in conjunction with the medical monitor and in accordance with the FDA 
“Guidance for Industry: Drug Induced Liver Injury- Pre-Marketing Clinical Evaluation” 
July 2009. 
5 
Data analysis 
Frequency and proportion of subjects deemed eligible and ineligible for study enrollment 
based on each of the inclusion/exclusion criteria will be summarized. The frequency and 
proportion of subjects who successfully complete the study, withdraw, were lost-to-follow-
up, and who terminated the study early, will also be reported. Subject characteristics at 
baseline will be summarized and described for all enrolled subjects and compared between 
the pre- and post-periods. Site characteristics will also be described. Descriptive statistics 
(count, mean, standard deviation, range for quantitative variables, and counts and percentages 
for categorical variables) will be reported for all outcomes. The difference in study outcomes 
between the pre- and post-period will be assessed using appropriate statistical methods, 
accounting for study site, with adequate power. The primary outcome will be tested for 
simple superiority, and subsequently, tested for non-inferiority with a 10% margin between 
the pre- and post-periods. 
All analyses will be specified in a detailed statistical analysis plan (SAP) that will be prepared 
subsequently and before database lock. The SAP will include table and figure shells.  
5.1 
Cost 
Cost data will not be collected in the study. As these data often vary by site and insurer, 
representative unit cost estimates for each healthcare service/medication identified during the 
collection of outcome measures will be identified. Total costs of care for each study subject 
will then be estimated by multiplying utilization of healthcare services collected via the CRF 
by the corresponding unit costs; mean/median total costs of care during the pre- and post-
periods will then be estimated and compared. The approach to the pre-post comparison and 
unit costs will be defined in the SAP. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 41 
Version 3.0  
5.2 
Handling of missing data  
The SAP will define how missing values and information from subjects lost to follow-up will 
be handled. Site procedures will be developed to minimize the amount of missing data 
however, as this is a pragmatic trial, missing data is expected. Certain outcomes are based on 
data availability from sites (e.g. laboratory values will be summarized for subjects who had 
data collected). 
The extent of missing values will be examined to assess completeness of data among the 
study cohort. In addition, the characteristics of participants with and without missing data 
will be examined to assess whether participant characteristics have any relationship to 
incompleteness.  
5.3 
Sample size and sample size considerations 
 
Hospital admission rate, which is correlated to total hospital time for the study population, 
was largely unknown for purposes of sample size estimation. The final enrollment to 
support hypothesis testing for a primary outcome of total admitted hospital days was 
initially calculated as 322 subjects (161 subjects in each period). The sample size was 
evaluated after a planned interim analysis of pre-period data once 75 subjects were enrolled 
in the pre-period. Based on results of the interim analysis, an adjustment was made at the 
time of the analysis to revise the primary outcome from total admitted hospital days to 
hospital admission rate at initial episode of care. The initially estimated final enrollment of 
322 subjects, including adjustments for attrition, would support one-sided hypothesis 
testing (two-sample Pearson chi-square test for proportion difference with equal group 
weights using a normal approximation) with a significance level of 0.05 and at least 80% 
power assuming hospital admission rate comparing the pre- and post-periods were 38% 
versus 23%. 
 
 
 
5.4 
Data monitoring and quality control 
Before any subject enters the study, a representative of the sponsor or CRO will meet with 
the investigator and core study team to review the procedures to be followed during the 
study. Electronic data capture (EDC) functionality training will be provided via computer 
to investigators and authorized designees on recording the data in the CRFs using the EDC 
system. All subject information and data will be considered private health information and 
kept confidential in compliance with HIPAA (Health Insurance Portability and 
Accountability Act of 1996). After the first subject is enrolled, the CRO representative will 
periodically monitor the progress of the study by conducting on-site visits. The CRO 
representative will review query statuses remotely, possibly warranting more frequent 
communication and/or site visits with the investigator and the study site staff. The 
investigator will make available to the CRO representative source documents (written notes 
and electronic medical records, if used), signed consent forms, and all other study-related 

Allergan Protocol: CMO-US-ID-0476 
 
Page 42 
Version 3.0  
documents. The investigator and the study site staff will be responsible for data entry of 
subject data into the CRFs via the EDC system, resolving data queries generated via the 
EDC system and providing missing or corrected data. The investigator or CRO 
representative will be responsible for approving all data entry and all changes performed on 
the data, and endorsing the subject data within the EDC system. 
Quality control will be implemented and maintained throughout the conduct of the study.  
Data collection will involve the use of the EDC system provided by the CRO, to which 
only authorized personnel will have access. Subject’s data will be entered into the EDC 
system by the investigator or designee using their assigned EDC user account as specified 
in Section 4.2 Data collection.  
6 
Study sites and study administrative structure 
 
This study will be performed at approximately 8 study centers in North America. 
6.1 
Core study team 
The core study team for each site will consist of primary investigators, CRO representatives, 
and sponsor representatives. The core study team will be responsible for training of the site 
study teams, responsible for adherence to the protocol, monitoring and reporting as consistent 
with regulation and law, and coordinating and participating in training sessions for the site 
study teams. The core study team is responsible for coordinating training of the site study 
teams for both protocol adherence and implementation and operationalization of the new 
critical pathway, including site-specific considerations. Training will occur before 
enrollment in the pre- and post-periods for adherence to the protocol. Training will 
additionally occur for implementation of the new critical pathway during the 2-4 weeks after 
the last subject is enrolled during the pre-period of the study. 
6.2 
Site study team 
The site study team at each site will consist of the primary site investigators and study 
administrators, including hospital staff (including physicians, nurses, and/or pharmacists), 
who will be responsible for adhering to the protocol for both the pre- and post-periods. The 
site study team will be further supported by the core study team, specifically, the CRO. The 
site study team will be responsible for participating in training sessions and/or engagement 
in communication from the core study team, in regards to study background/rationale, site 
procedures to identify and enroll subjects who are eligible for the study during the pre- and 
post-periods, data collection, and follow-up of subjects. Specifically, for the post-period, 
training on the implementation of the new critical pathway is vital. Training will include site 
procedures, such as how to obtain study drug during the post-period from the hospital 
pharmacy and the location to administer study drug. This will ensure adherence to the 
protocol and that operationalization of the study is consistent during both study periods. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 43 
Version 3.0  
7 
Ethical considerations  
7.1 
Regulatory and ethical compliance and protection of human subjects 
To ensure safety of participating subjects, this study will be conducted in compliance with 
the protocol, the rules and regulations of each institutional review board (IRB), informed 
consent regulations, and standard operating procedures (SOP) at CRO, sponsor, and each 
study site. This study will adhere to all applicable local regulatory requirements and be 
governed according to local laws and regulations. The following rules, regulations, and 
practices will be adhered to: Good Clinical Practice (GCP) guidelines, International 
Conference on Harmonisation (ICH) Guidelines, Declaration of Helsinki, and the Belmont 
Report. 
7.2 
Subject confidentiality 
All necessary measures will take place to ensure subject confidentiality. Only site study team 
members and an independent unit of the CRO will know the identity of participating subjects, 
however no identifying information will be collected on any study-related documents. 
Contact information for the subject after their consent will be sent to an independent unit of 
the CRO, where it will be kept confidential, and will only be used to contact the patient for 
pre-determined study visits. Any data provided to CRO or sponsor will be de-identified by 
using the unique subject ID. Neither CRO nor sponsor will have access to any subject 
identification log. Any data reported or published will be presented as aggregated data, and 
no individual data will be reported to reduce any risk of subject identification. 
7.3 
Informed consent procedures 
 
Patients, after being given an explanation of the study, will give voluntary and written 
informed consent and HIPAA (Health Insurance Portability and Accountability Act of 
1996) authorization (in compliance with 21 CFR, Parts 50 and 312) or other appropriate 
documentation, according to local regulatory requirements, before participating in any 
study-related procedures. 
Informed consent will be obtained from each subject prior to the beginning of any study-
specific activities, and will include consent to collection of clinical, economic and humanistic 
outcomes. This may involve gathering data through chart review or directly eliciting 
information from subjects. Informed consent during the post-period, or interventional period, 
will involve consent to treatment through a new critical pathway. Each eligible subject will 
have the opportunity to read and review the approved informed consent form (ICF) and have 
the opportunity to ask questions to the participating Study Investigator, Study Coordinator, 
or other study team member. Signed copies of the ICF and the HIPAA or other locally 
applicable form will be given to the subject, and both documents will be placed in the 
investigator’s study files. 
The participating subject may withdraw participation and/or informed consent at any time 
throughout the conduct of the study. Withdrawing participation or consent will relieve the 
subject from any future data collection time points.  

Allergan Protocol: CMO-US-ID-0476 
 
Page 44 
Version 3.0  
7.4 
Responsibilities of the investigator and IRB 
The responsibilities of investigators include creation of and maintenance of a core study team 
(Please refer to Section 7 for more information), adhering to protocol requirements, including 
educational requirements for implementation of the intervention in the post-period, and 
ultimately, are the institutional leads to support protocol implementation. The study team will 
be responsible for timely reporting, where appropriate, to the institutional IRB. The 
investigators must demonstrate reasonable efforts to obtain qualified patients for the study. 
The responsibilities of the IRB include adhering to institutional requirements,  performing an 
objective review of the acceptability of the study protocol and analysis plan (i.e. research) in 
terms of institutional requirements, commitments, regulations, applicable law, and 
professional conduct and practice, provide continued monitoring and review of research, 
review of key events (protocol amendments, protocol deviations, adverse events, or non-
compliance), review of any required progress reports, and to report any required information 
to appropriate authorities and/or organizations.  
7.5 
Publication  
All data generated in this study are the property of the sponsor. An integrated clinical and 
statistical analysis report will be prepared at the completion of the study.  
Publication of the results by the investigator will be subject to mutual agreement between the 
investigator and the sponsor and will follow the sponsor’s SOP on publications. 
8 
Protocol deviations and violations 
A protocol deviation is any change, divergence, or departure from the study design or 
procedures that is under the investigator’s responsibility and oversight (as defined by 
regulations) without prior written IRB approval or favorable opinion of an appropriate 
amendment and that does not have a major impact on the subject’s rights, safety, or well- 
being, or on the integrity and authenticity of the study data. Deviations may include, but are 
not limited to, departure from inclusion/exclusion criteria, dosing, duration of treatment, 
failure to perform the required assessments at specified time points, scheduling of visits not 
in accordance with specifications, or subject safety. Deviating from the protocol is permitted 
only if absolutely necessary for the safety or clinical management of the subjects and will 
immediately be reported to the sponsor. Protocol deviations will be reported to the sponsor 
either verbally or electronically within 5 working days from the day of discovery. 
A protocol violation is a form of protocol deviation that has a major impact on the subject’s 
rights, safety, or well-being, or on the integrity and authenticity of the study data. Protocol 
violations will be reported to the sponsor within 24 hours, if possible. The IRB will be 
notified within the time period dictated by the IRB associated with this study. 
8.1 
Protocol amendments 
Any amendment to this protocol will be provided to the investigator in writing by the 
sponsor. No protocol amendment will be implemented (with the exceptions noted below) 
before it has been approved by the IRB and the signature page, signed by the investigator, 
has been received by the sponsor. If the protocol is amended to eliminate or reduce the risk 

Allergan Protocol: CMO-US-ID-0476 
 
Page 45 
Version 3.0  
to subjects, the amendment will be implemented before IRB review and approval. 
However, the IRB will be informed in writing of such an amendment, and approval will be 
obtained within reasonable time limits. 
9 
References  
1. 
US Department of Health and Human Services, US Food and Drug Administration, US 
Center for Drug Evaluation and Research. Guidance for Industry - Acute Bacterial Skin and 
Skin Structure Infections: Developing Drugs for Treatment. October 2013; 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf. Accessed January 29, 
2016. 
2. 
Amin AN, Cerceo EA, Deitelzweig SB, Pile JC, Rosenberg DJ, Sherman BM. Hospitalist 
perspective on the treatment of skin and soft tissue infections. Mayo Clin. Proc. 
2014;89(10):1436-1451. 
3. 
Pollack CV, Jr., Amin A, Ford WT, Jr., et al. Acute bacterial skin and skin structure 
infections (ABSSSI): practice guidelines for management and care transitions in the 
emergency department and hospital. J. Emerg. Med. 2015;48(4):508-519. 
4. 
Pallin DJ, Camargo CA, Jr., Schuur JD. Skin infections and antibiotic stewardship: analysis 
of emergency department prescribing practices, 2007-2010. West. J. Emerg. Med. 
2014;15(3):282-289. 
5. 
Lee GC, Boyd NK, Lawson KA, Frei CR. Incidence and cost of skin and soft tissue 
infections in the United States. Paper presented at: ISPOR 20th Annual International 
Meeting2015; Philadelphia, PA, USA. 
6. 
Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft 
tissue infections. Emerg. Infect. Dis. 2009;15(9):1516-1518. 
7. 
Healthcare Cost and Utilization Project (HCUP). Statistical Brief #162. Most Frequent 
Conditions in U.S. Hospitals. 2011; http://www.hcup-
us.ahrq.gov/reports/statbriefs/sb162.pdf. Accessed May 31, 2016. 
8. 
Berger A, Weber DJ, Boening AJ, et al. Poster No. 288: Patterns of initial antibiotic therapy 
in hospitalized patients with complicated skin and skin structure infections (cSSSI) in the 
US: 2007 - 2010. Paper presented at: IDSA 49th Annual Meeting2011; Boston, MA, USA. 
9. 
Berger A, Edelsberg J, Oster G, et al. Patterns of initial antibiotic therapy for complicated 
skin and skin structure infections (cSSSI) in US hospitals, 2000-2009. Infect Dis Clin 
Pract. 2013;21:159-167. 
10. 
Talan DA, Salhi BA, Moran GJ, et al. Factors associated with decision to hospitalize 
emergency department patients with skin and soft tissue infection. West. J. Emerg. Med. 
2015;16(1):89-97. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 46 
Version 3.0  
11. 
Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral 
antimicrobial therapy. IDSA guidelines. Clin. Infect. Dis. 2004;38(12):1651-1672. 
12. 
Allergan. Prescribing information: Dalvance (dalbavancin). 2014; 
http://www.allergan.com/assets/pdf/dalvance_pi. Accessed January 29, 2016. 
13. 
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly 
dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 
2014;370(23):2169-2179. 
14. 
Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-
weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated 
skin and skin structure infections. Clin. Infect. Dis. 2005;41(10):1407-1415. 
15. 
Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care 
antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 
2003;37(10):1298-1303. 
16. 
Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A 
Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of 
Acute Bacterial Skin and Skin Structure Infection. Clin. Infect. Dis. 2015. 
17. 
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and 
management of skin and soft tissue infections: 2014 update by the Infectious Diseases 
Society of America. Clin. Infect. Dis. 2014;59(2):e10-52. 
18. 
The Medical Letter. Handbook of Antimicrobial Therapy, 18th edition.  
http://secure.medicalletter.org/handbooks#hat. Accessed January 29, 2016. 
19. 
Forest Laboratories I. Prescribing information: Teflaro (ceftaroline fosamil) injection for 
intravenous (IV) use. 2010; 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200327s000lbl.pdf. Accessed 
January 29, 2016. 
20. 
Theravance I. Prescribing information: VIBATIV (televancin) for injection, for intravenous 
use. 2009; http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf. 
Accessed January 29, 2016. 
21. 
Merck. Prescribing information: SIVEXTRO (tedizolid phosphate) for injection, for 
intravenous use; SIVEXTRO (tedizolid phosphate) tablet, for oral use. 2014; 
https://www.merck.com/product/usa/pi_circulars/s/sivextro/sivextro_pi.pdf. Accessed 
January 29, 2016. 
22. 
The Medicines Company. Prescribing information: ORBACTIV (oritavancin) for injection, 
for intravenous use. 2014; 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf. Accessed 
January 29, 2016. 

Allergan Protocol: CMO-US-ID-0476 
 
Page 47 
Version 3.0  
23. 
Triax Pharmaceuticals L. Prescribing information: MINOCIN, Minocycline For Injection 
100 Mg/Vial Intravenous 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050444s047lbl.pdf. Accessed 
January 29, 2016. 
24. 
Cubist Pharmaceuticals. Tedizolid phosphate for the treatment of acute bacterial skin and 
skin structure infections. March 31, 2014; 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
Anti-InfectiveDrugsAdvisoryCommittee/UCM390790.pdf. Accessed January 29, 2016. 
25. 
Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and 
interpreting clinical trials. Clin. Infect. Dis. 2014;58 Suppl 1:S4-9. 
26. 
Surviving Sepsis Campaign. International Guidelines for Management of Severe Sepsis and 
Septic Shock. 2012; http://www.sccm.org/Documents/SSC-Guidelines.pdf. Accessed 
January 29, 2016. 
27. 
American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference: definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. Crit. Care Med. 1992;20(6):864-874. 
28. 
Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory 
response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 2015;372(17):1629-
1638. 
29. 
Cohen J. Infection in the immunocompromised host In: Warrell DA, Cox TM, Firth JD, 
eds. Oxford Textbook of Medicine, 5th edition. 
30. 
Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work 
productivity and activity impairment questionnaire--general health version in patients with 
rheumatoid arthritis. Arthritis Res. Ther. 2010;12(5):R177. 
31. 
Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score the Version 2 of the 
SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: Quality 
Metric; 2002. 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 48 
Version 3.0  
10 
Appendices 
10.1 
Measurement of lesion characteristics 
 
Measurements are to be taken while the infected area is in a nondependent position, e.g., if infection 
was on the leg, the subject was lying down, not sitting or standing. All types of infections are to be 
measured as measurement of erythema upon enrollment and any subsequent physical follow-up visits. 
Maximal dimensions of erythema, both width and length, are to be recorded in centimeters. 
Investigators should attempt to find the infection edge that best distinguished erythema from non-
erythematous skin. Erythema is to be measured in the dimension of maximal length. The maximal 
width is to be measured perpendicular to the axis of the maximal length. The maximal width 
measurement does not have to be in the center if the area of erythema is irregular. The length of the 
infection is to be multiplied by perpendicular width of wound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 49 
Version 3.0  
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 50 
Version 3.0  

Allergan Protocol: CMO-US-ID-0476 
 
Page 51 
Version 3.0  
 
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 52 
Version 3.0  
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 53 
Version 3.0  

Allergan Protocol: CMO-US-ID-0476 
 
Page 54 
Version 3.0  
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 55 
Version 3.0  
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 56 
Version 3.0  
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 57 
Version 3.0  
 
 
 
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 58 
Version 3.0  
 

Allergan Protocol: CMO-US-ID-0476 
 
Page 59 
Version 3.0  

Allergan Protocol: CMO-US-ID-0476 
 
Page 60 
Version 3.0  

Allergan 
Confidential 
Page 61 
Protocol 
 
 
 
 
Allergan Protocol: CMO-US-ID-0476 
 
Page 61 
Version 3.0